FDA Grants Priority Review for ENHERTU Supplement Application
The FDA has granted priority review status for the supplemental application of ENHERTU (BLA761139) by Daiichi Sankyo.
Asset
ENHERTU
Indication
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The FDA's grant of priority review for ENHERTU's supplemental application is a significant regulatory milestone that could accelerate its market entry. This development positions Daiichi Sankyo to enhance its competitive stance in the oncology sector, particularly in HER2-targeted therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's final decision timeline and any announcements regarding additional data requirements or indications.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.